reversed-phase HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
1P-LSD, also known as 1-propionyl-LSD, is a psychedelic drug of the lysergamide family related to LSD. It is an amide derivative of LSD and a homologue of ALD-52 (1A-LSD). The drug originated in 2015 when it appeared as a designer drug sold online. It was first synthesized as a legal LSD alternative by Lizard Labs, a Netherlands based research chemical laboratory. It modifies the LSD molecule by adding a propionyl group to the nitrogen atom of LSD's indole group and is a prodrug of LSD.
The delineation of each of the two lobes of the flap begins and ends at the inner semi-circle, and extends to the outer semi-circle, to the point where it intersects its central axis. The width of the first lobe is approximately 2 mm narrower than the width of the wound; the width of the second lobe is approximately 2 mm narrower than the width of the first lobe. After the cutting from the tissue donor-site, the bilobed flap is elevated to a plane between the subcutaneous fat and the nasalis muscle. The wound is deepened, down to the nasal skeleton, to accommodate the tissue thickness of the bilobed flap. Technically, cutting the wound, enlarging it, is preferable, and safer, than trimming (thinning) the flap to fit the wound. Undermining the donor site for the second lobe allows closing it primarily; it also eliminates excess-skin "dog-ears" at the donor site. Moreover, if the donor site cannot be closed with sutures, or if the skin blanches (whitens) when sutured, usually because of excessively tight sutures, the tension is decreased by reducing the size (length, width, depth) of the wound with deep sutures that will allow it to heal more readily. II. Nasolabial flap In the 19th century, the surgical techniques of J.F. Dieffenbach (1792–1847) popularized the nasolabial flap for nasal reconstruction, for which it remains a foundational nose surgery procedure.
The chain quit the Philippine market in 2004 owing to several factors: lack of interest in its standard fare, lack of interest among locals, expensive cost and a general sense of unfamiliarity with local palates. The chain failed to adapt to local tastes and quietly shut down in the summer of 2004.
Particle size after micronization is most commonly measured by laser diffraction under USP general chapter <429> and the harmonized ISO 13320 standard, and reported as the volume-weighted D10, D50 and D90 statistics. High-energy mechanical micronization can introduce surface amorphization, polymorphic conversion and triboelectric charging, all of which affect downstream stability and processability and often require post-milling conditioning to control.
==== Non-B cell tumors ==== Hypoglycemia may occur in people with non-B cell tumors such as hepatomas, adrenocorticoid carcinomas, and carcinoid tumors. These tumors lead to a state of increased insulin, specifically increased insulin-like growth factor II, which decreases glucose levels.
Sources: en.wikipedia.org
== Biography == Pierluigi Christophe Orunesu established Cybel’Art, a company that developed XR, digital and holographic protocol called icologram. His company collaborated with various artists, including Philippe Entremont and Henri Dès. In 2008 in Switzerland, Orunesu founded Eurolactis, a business focused on the processing and distribution of Donkey's milk. His company operates worldwide and has a research team in Italy. In 2011, Eurolactis signed a partnership agreement with football club Inter Milan. In 2017, he stepped down from the presidency, but remained involved as the general manager. In December 2014, he donated two donkey foals and freeze-dried donkey milk to Pope Francis, intended for the Vatican hospitals. In 2016, Pierluigi Christophe Orunesu collaborated with Swiss master chocolatier Gérard Fornerod to create "Quartier des Ânes," the first Swiss chocolate bar made with donkey milk, marking an unprecedented innovation in the history of Swiss chocolate-making. In 2020, Pierluigi Christophe Orunesu was invited to testify at the Agriculture and Agri-Food Commission of the Italian Senate as CEO of Eurolactis, in the context of Bill No. 1197 on the valorization of the Italian Donkey milk production chain. His expert testimony contributed to the legislative discussion aimed at increasing Donkey milk production for human consumption in Italy. In 2023, his company, Cybel’Art, launched icologram App, a digital and spatial computing startup that allows the virtual presence of artists, such as Henri Dès, through augmented reality technology.
== History == Dutasteride was patented in 1996 and was first described in the scientific literature in 1997. It was approved by the FDA for the treatment of BPH in November 2001, and was introduced on the United States market the following year under the brand name Avodart. Dutasteride has subsequently been introduced throughout the world. The patent protection of dutasteride expired in November 2015, so the drug has since become available in the United States in a variety of low-cost generic formulations. It was approved for the treatment of scalp hair loss in South Korea in 2009, in Japan in 2015 and in Taiwan in 2016. It has not been approved for this indication in the United States, though it is often used off-label both orally and topically.
=== Tumor suppressor === Loss-of-heterozygosity (LOH) of the 7q22.1 chromosomal region, where CUX1 resides, was reported in 8–22% of various cancer, and in close to 50% in therapy-associated leukemias. As no inactivating mutations were found in the remaining allele, the notion that CUX1 could be the tumor suppressor gene on 7q22.1 was dismissed for some time. However, refined mapping in leiomyomas and myeloid leukemias eventually pointed to CUX1 as the sole tumor suppressor gene in this region. These genetic data suggest that CUX1 may be a haploinsufficient tumor suppressor gene. In addition to LOH events, large scale DNA sequencing identified inactivating point mutations in 1–5% of cancers where both alleles are present. There is no tumor case where both CUX1 allele are inactivated. While the biochemical activities of CUX1 that explain its role in tumor maintenance and progression have been well defined, the biochemical functions of CUX1 involved in tumor suppression have yet to be firmly established. Two mechanisms have been proposed. One study reported that CUX1 functions as a transcriptional activator of PIK3IP1, a gene that codes for the phosphoinositide-3-kinase interacting protein 1 (PIK3IP1), a direct inhibitor of the PI3K p110 catalytic subunit. CUX1 knockdown caused a decrease in PIK3IP1 expression that was associated with an increase in PI3K signaling and AKT signaling. A separate study, however, argued that CUX1 is itself a target of AKT signaling.
In August 2022, Lee and Lifeson returned to the stage at the South Park 25th anniversary concert at Red Rocks Amphitheatre, with South Park's co-creator Matt Stone on drums to perform "Closer to the Heart" alongside the members of Primus; this was their first performance since the death of Peart. In September 2022, Lee and Lifeson performed at the London Taylor Hawkins tribute concert with Dave Grohl and Omar Hakim on drums. They performed "2112: Overture", "Working Man", and "YYZ", the latter of which was Hawkins' favourite Rush song. Later in September 2022, Lee and Lifeson played the same set at the second Taylor Hawkins Tribute show in Los Angeles. Grohl was the drummer again on "2112", Chad Smith of the Red Hot Chili Peppers joined them for "Working Man", and Danny Carey from Tool played drums for "YYZ". Those appearances fuelled speculation over a possible Rush reunion, with Paul McCartney (who attended the Hawkins tribute shows) urging Lee and Lifeson to tour again, and Smith commenting, "Those guys are so happy to be playing again... They were part of the show. They loved it and enjoyed the hell out of it. Those guys miss playing.
Sources: en.wikipedia.org
After Rojas' deposition, the Colombian Conservative Party and the Colombian Liberal Party agreed to create the National Front, a coalition that would jointly govern the country. Under the deal, the presidency would alternate between conservatives and liberals every 4 years for 16 years; the two parties would have parity in all other elective offices. The National Front ended "La Violencia", and National Front administrations attempted to institute far-reaching social and economic reforms in cooperation with the Alliance for Progress. Despite the progress in certain sectors, many social and political problems continued, and guerrilla groups were formally created such as the FARC, the ELN and the M-19 to fight the government and political apparatus. Since the 1960s, the country has suffered from an asymmetric low-intensity armed conflict between government forces, leftist guerrilla groups and right wing paramilitaries. The conflict escalated in the 1990s, mainly in remote rural areas. Since the beginning of the armed conflict, human rights defenders have fought for the respect for human rights, despite staggering opposition. Several guerrillas' organizations decided to demobilize after peace negotiations in 1989–1994. The United States has been heavily involved in the conflict since its beginnings, when in the early 1960s the U.S. government encouraged the Colombian military to attack leftist militias in rural Colombia. This was part of the U.S. fight against communism.
=== Research supporting the development, safety and benefits of GLP-1 therapeutics === Drucker joined the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto in 2006. In 2008 he led studies aimed at the development and testing of the first long-acting, once-weekly version of the diabetes medication exenatide. He later studied the long-term effects of related weight-loss medicines on bowel health. Drucker has also led the identification of the cardioprotective mechanisms of GLP-1 action. Notably, in 2009 he demonstrated in mice that these effects were not dependent on glucose lowering or weight loss – findings confirmed over a decade later in cardiovascular outcome trials. His discoveries predicted the safety of GLP-1 receptor agonists for their expanding applications to treat obesity and other chronic conditions. Most recently, Drucker has identified multiple mechanisms linking GLP-1 to the reduction of inflammation. Drucker holds the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. His many national and international recognitions include the 2023 Wolf Prize in Medicine, awarded for "pioneering work in elucidating the mechanisms and therapeutic potential of enteroendocrine hormones," as well as the Warren Alpert Foundation Prize and the Canada Gairdner International Award, among numerous others. Drucker was elected a Royal Society Fellow in 2015, a National Academy of Sciences International Member in 2021and a National Academy of Medicine International Member in 2023.
The album was noted for its performance style, that occasionally veered towards funk, and for Burrell's scat singing on the improvised pieces, but was criticised for its poor sound quality. Better-quality live recordings from this era would be released in 2002 as Ladies of the Road and in 2017 on the Sailors' Tales (1970–1972) box set. By this time the musical rift between Fripp and the rest of the band had grown very wide. Wallace, Burrell, and Collins favoured improvised blues- and funk-influenced music; Fripp would later describe the 1971–1972 line-up as more of a jam band than an "improvising" band, an opinion with which Wallace disagreed. Personal relations, however, improved during the tour to the point where most of the band wanted to continue; nonetheless, Fripp opted to part company with the other three and reconstitute King Crimson with new musicians, as he felt the other members would not fully engage with the musical direction he now had in mind. Collins went on to join Camel, Burrell co-formed Bad Company, and Wallace became a session musician, most notably playing on several Bob Dylan albums and the Traveling Wilburys' first album.
=== Ba'athist rule (1963–2024) === Following the 1963 coup, the People's Assembly largely served as a rubber stamp for the ruling Ba'athists. Only parties affiliated with the National Progressive Front could participate in elections. The 2012 elections, held on 7 May, resulted in a new parliament that, for the first time in four decades, was nominally based on a multi-party system. The opposition was represented by the Popular Front for Change and Liberation, which won six seats. It later boycotted the 2016 elections as the government had not upheld its pledges to seek constitutional amendments and pursue political negotiations. In 2016, Hadiya Khalaf Abbas, whom had represented Deir ez-Zor since 2003, became the first woman elected to be the Speaker, whilst in 2017, Hammouda Sabbagh became the first Syriac Orthodox Christian to have held the post.
In return, the host provides the symbiont with chemicals required for chemosynthesis, such as carbon, sulfide, and oxygen. In the early stages of studying life at hydrothermal vents, there were differing theories regarding the mechanisms by which multicellular organisms were able to acquire nutrients from these environments, and how they were able to survive in such extreme conditions. In 1977, it was hypothesized that the chemoautotrophic bacteria at hydrothermal vents might be responsible for contributing to the diet of suspension-feeding bivalves. Finally, in 1981, it was understood that giant tubeworm nutrition acquisition occurred as a result of chemoautotrophic bacterial endosymbionts. As scientists continued to study life at hydrothermal vents, it was understood that symbiotic relationships between chemoautotrophs and macrofauna invertebrate species was ubiquitous. For instance, in 1983, clam gill tissue was confirmed to contain bacterial endosymbionts; in 1984 vent bathymodiolid mussels and vesicomyid clams were also found to carry endosymbionts. However, the mechanisms by which organisms acquire their symbionts differ, as do the metabolic relationships. For instance, tubeworms have no mouth and no gut, but they do have a "trophosome", which is where they deal with nutrition and where their endosymbionts are found. They also have a bright red plume, which they use to uptake compounds such as O, H2S, and CO2, which feed the endosymbionts in their trophosome.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。